Literature DB >> 16713481

Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept.

James M Krell1.   

Abstract

This article reports on the combined use of alefacept and etanercept in 3 patients whose psoriasis failed to respond adequately to etanercept. All patients maintained improvement for at least 8 weeks after completing 12 weeks of alefacept. No adverse events or infections were reported, and CD4+ T-cell counts remained above normal limits.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16713481     DOI: 10.1016/j.jaad.2005.08.032

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

Review 1.  Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients.

Authors:  Eduard Brunet Mas; Xavier Calvet Calvo
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

2.  The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis.

Authors:  Claudia Jenneck; Natalija Novak
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.